Published in final edited form as:

Biochemistry. 2011 May 10; 50(18): 3660–3672. doi:10.1021/bi2000559.

Solution NMR Insights into Docking Interactions Involving Inactive ERK2†

Andrea Piserchio¹, Mangalika Warthaka², Ashwini K. Devkota³, Tamer S. Kaoud^{2,4}, Sunbae Lee², Olga Abramczyk², Pengyu Ren^{3,5}, Kevin N. Dalby^{2,3,4,5,6,*}, and Ranajeet Ghose^{1,7,*}

¹ Department of Chemistry, The City College of New York, New York, NY 10031

² Division of Medicinal Chemistry, University of Texas, Austin, TX 78712

³ Graduate Program in Cellular and Molecular Biology, University of Texas, Austin, TX 78712

⁴ Graduate Program in Pharmacy, University of Texas, Austin, TX 78712

⁵ Graduate Program in Biomedical Engineering, University of Texas, Austin, TX 78712

⁶ Graduate Program in Biochemistry, University of Texas, Austin, TX 78712

⁷ The Graduate Center of CUNY, New York, NY 10016

Abstract

The mitogen activated protein (MAP) kinase ERK2 contains recruitment sites that engage canonical and non-canonical motifs found in a variety of upstream kinases, regulating phosphatases and downstream targets. Interactions involving two of these sites, the D-recruitment site (DRS) and the F-recruitment site (FRS), have been shown to play a key role in signal transduction by ERK/MAP kinases. The dynamic nature of these recruitment events makes NMR uniquely suited to provide significant insight into these interactions. While NMR studies of kinases in general have been greatly hindered by their large size and complex dynamic behavior leading to the sub-optimal performance of standard methodologies, we have overcome these difficulties for inactive full-length ERK2 and obtained an acceptable level of backbone resonance assignments. This allowed a detailed investigation of the structural perturbations that accompany interactions involving both canonical and non-canonical recruitment events. No crystallographic information exists for the latter. We found that the chemical shift perturbations in inactive ERK2, indicative of structural changes in the presence of canonical and non-canonical motifs, are not restricted to the recruitment sites, but also involve the linker that connects the *N*- and *C*-lobes and, in most cases, a gatekeeper residue that is thought to exert allosteric control over catalytic activity. We also found that, even though the canonical motifs interact with the DRS utilizing both charge-charge and hydrophobic interactions, the non-canonical interactions primarily involve the latter.

†This research has been supported by the following grants from the National Institutes of Health: GM084278 (to RG), GM059802 (to KND), GM079686 (to PR) and 5G12 RR03060 (towards partial support of the NMR facilities at The City College of New York). RG is a member of the New York Structural Biology Center, NYSTAR facility. KND is a recipient of a grant from the Welch Foundation (F-1390). Computing resources were provided by TeraGrid (MCB100057).

*Address correspondence to: Ranajeet Ghose Ph.D., 160 Convent Avenue, New York, NY 10031. Fax: (212)-650-6107, Phone: (212) 650-6049, rghose@sci.ccny.cuny.edu OR Kevin N. Dalby Ph.D., 107 West Dean Keaton, Biomedical Engineering Building, University of Texas at Austin, TX 78712. Fax: (512) 232-2606, Phone: (512) 232-1832, kinases@me.com.

SUPPORTING INFORMATION AVAILABLE

Representative titration series for ERK2 in the presence of ligand. Close-up view of chemical shift perturbations and availability of resonance assignments at the FRS in inactive ERK2. Cysteine foot-printing studies on ERK2 (L232C) in the presence and absence of *Ets*. A computational model for a complex of *Ets* with active ERK2. This material is available free of charge via the Internet at <http://pubs.acs.org>.

These results demonstrate the feasibility of solution NMR techniques for a comprehensive analysis of docking interactions in a full-length ERK/MAP kinase.

Extracellular signal-regulated kinases (ERK) constitute a sub-family of mitogen activated protein (MAP) kinases that undergo up-regulation upon activation of cell surface receptors by extracellular events such as binding of cytokines or growth factors (1–3). ERKs play a central role in growth-factor related apoptosis in colorectal cancer (4) and the ERK signaling pathway is a key target for anti-cancer therapeutics (5, 6). Activation of ERKs (ERK1 and ERK2) occurs downstream of the Ras/Raf pathway upon dual phosphorylation of a conserved T-X-Y motif ($^{183}\text{T-X-Y}^{185}$ in ERK2) in the activation loop by MAPKKs (MAP/ERK kinase kinase). Activated ERKs phosphorylate a host of downstream targets both in the cytosol (7, 8) and in the nucleus (9). Down-regulation of enzymatic activity occurs by single or dual de-phosphorylation by serine/threonine, tyrosine or dual-specificity phosphatases (3). ERKs (see Figure 1) possess a catalytic domain containing the archetypal motifs present in protein kinases (10, 11), but do not possess any additional regulatory domains unlike, for example, the Src-family kinases (12). A feature of MAPKs (including ERKs) is the presence of the so-called “MAP kinase insert” between the αG and αH helices and of an α -helical C-terminal extension (see Figure 1). The MAP kinase insert has been deemed to be important in protein-protein interactions involving a host of regulators (13, 14) and substrates (15).

MAP kinases, including ERK1/2, utilize specific docking or recruitment sites distinct from the active site to recognize substrate or regulatory motifs (16, 17). These regulatory interactions occur with up-regulating MAPKKs, adaptor proteins, and down-regulating phosphatases (18). Among the best-characterized MAP kinase-docking motifs is one variously known as a D-site, D-motif, kinase interaction motif (KIM) or DEJL motif, which contains a conserved $(\text{R/K})_{2-3}\text{-X}_{2-6}\text{-}\Phi_{\text{A}}\text{-X-}\Phi_{\text{B}}$ sequence (Φ_{A} and Φ_{B} are hydrophobic residues). Crystal structures of MAP kinases complexed with D-site peptides have revealed insights into the structural basis of these interactions (19). These studies have shown that basic residues of the D-site bind to a negatively charged surface (Φ_{chg} , containing two common-docking Asp residues (20)) and the $\Phi_{\text{A}}\text{-X-}\Phi_{\text{B}}$ sequence binds to a nearby hydrophobic docking (Φ_{hyd}) pocket on the surface of the kinase. These two sites, Φ_{chg} and Φ_{hyd} , constitute the D-recruitment site (DRS) on ERK2. It has been shown that binding at the DRS can induce long-range conformational changes in the kinase (17, 21–23). Structures of ERK2 bound to D-site peptides from the phosphatases MKP3 (23) and HePTP (24) showed similar conformational transitions of the activation loop, which adopted a configuration similar to the active state. Recent results suggest a role for D-site interactions in the allosteric regulation of kinase activity in ERKs (25). In addition, a second docking motif deemed important for target recognition has been identified (21). The “DEF” motif (docking site for ERK FXFP) or F-site contains a FXFP sequence that is conserved in multiple ERK targets including Elk-1, c-Fos, SAP1 and the kinase suppressor of Ras (KSR). A library-scan analysis suggests that either F in the FXFP motif may be substituted for Y or W (26). Unlike the DRS, no clear crystallographic information exists for the nature of interactions that define the F-recruitment site (FRS). However, key residues that define this site have been identified using hydrogen exchange mass spectrometry (HXMS) coupled with mutational analysis (21). It was shown that Y231, L232, L235 on one side of a hydrophobic groove on ERK2 together with M197, L198 and Y261 were crucial in defining the FRS and interacting with F-site sequences. Mutation of the residues Y231, L232, L235 and Y261 to Ala in active ERK2 leads to significant reduction in binding (21). These data allowed a model of an F-site peptide from Elk-1 bound at the FRS to be obtained (21). It was also suggested that this site is only partially formed in inactive ERK2. However, at least partial use of this site, both in the active as well as in the inactive enzyme, has been noted for the transcription factor Ets-1, an ERK2 substrate which lacks a canonical F-site sequence (27).

In addition, the anti-apoptotic adaptor protein PEA-15, which also lacks a canonical F-site sequence, has been suggested to bind at a site proximal to the FRS (14, 28) both in active and inactive ERK2. In both cases the DRS is also extensively involved in promoting these non-canonical interactions (28, 29).

Given the central importance of these docking interactions, their structural and dynamic characterization is crucial for understanding their role in the regulation of MAP kinase signal transduction pathways (e.g. in ERK2). This is especially true for the non-canonical ligands described above, for which extensive biochemical information (14, 15, 21, 27, 28), but no structural data are available. Several of these non-canonical interactions involve intrinsically disordered segments that likely retain a substantial portion of their flexibility after complex formation. This is a possible reason why the complexes have evaded crystallization (27, 28). Given these issues, solution NMR techniques seem ideally suited to study docking interactions on ERK/MAP kinases. NMR studies are expected to enhance and expand crystallographic information available for canonical D-site interactions in the ERK/MAP kinase family, providing information about variability in these associations involving different D-site ligands. For interactions that involve canonical F-site sequences and non-canonical ligands, these studies are expected to confirm mutational analyses and allow their interpretation in structural terms. The large size of the ERK/MAP kinases (>40 kDa), their instability under the high concentrations required for NMR experiments and their complex dynamics lead to a failure of conventional techniques for resonance assignment. This is a common problem in the NMR studies of protein kinases and therefore only a handful of NMR analyses of these key signaling enzymes have appeared in the literature. These include protein kinase A (30, 31), the catalytic domain of c-Abl (32), the ERK2 homolog p38 α (33, 34) and the catalytic domain of the Eph receptor tyrosine kinase (35).

Given that for ERK2 extensive structural, biochemical and functional information on docking interactions is available, we undertook the task of obtaining resonance assignments to investigate the structural and dynamic effects of these interactions. Here, as a first step towards this goal, we present an analysis of canonical and non-canonical docking interactions involving full-length inactive ERK2 using solution NMR techniques. Our studies demonstrate the feasibility of using solution NMR methodology to study protein-protein interactions involving a full-length ERK/MAP kinase, and represent the very first comprehensive NMR analysis of protein-protein interactions for ERK/MAP kinase family. Our results provide unique insight into the variability of these interactions and also into the network of connectivity that propagates from the recruitment sites into remote regions of the protein. They also confirm the results of the mutational analyses and demonstrate that interactions involving sequences that do not carry canonical D- or F-sites can also engage the DRS and FRS.

MATERIALS AND METHODS

Protein Expression and Purification

BL21 (DE3)-T1 competent *E. coli* cells were transformed with a pET28 vector coding for an N-terminal His₆ tag, a thrombin cleavage site, and the sequence of full-length rat ERK2 (Kaoud, T. S. et al. manuscript in preparation). Starting from a fresh transformation, cells were grown overnight in 20 mL of M9 media in a shaking incubator (37°C, 250 rpm). The following day, the cells were diluted with fresh media to prepare 10 mL of an M9 culture containing 10% D₂O, with a starting OD₆₀₀ of 0.2. When the OD₆₀₀ reached 0.6, the cells were diluted by a factor of two using a stock of M9 media in 100% D₂O (10 mL total volume). This operation was repeated several times, until the cells were adapted for growth in 98% D₂O. For all the adaptation steps, we used 8 g/L glucose and 1 g/L ammonium chloride. The adapted cells were then used to inoculate a new M9 culture prepared in 100%

D₂O containing 5 g/L ¹³C, ²H glucose and 1 g/L ¹⁵NH₄Cl, and incubated overnight. The cells were used the following morning to inoculate 0.5 L M9 medium prepared in 100% D₂O containing 3 g/L ²H, ¹³C glucose and 1 g/L ¹⁵NH₄Cl. At an OD₆₀₀ of 0.6, the cells were transferred on ice for 0.5 h, induced with 400 μM IPTG to over-express uniformly ²H, ¹⁵N, ¹³C-labeled ERK2, and transferred into a shaking incubator set to 17°C for 24 h. The cells were then spun down at 7000 g and stored at -80°C for future manipulations. All media were supplemented with 50 mg/L of kanamycin.

Samples containing amino acids selectively ¹³CO-labeled in a uniformly ²H,¹⁵N-labeled background were produced following the protocol developed by Takeuchi and coworkers (36). Briefly, the same recipe described above was applied with the following modifications: ²H,¹²C glucose was used for both the final overnight and for the final large-scale growth. For the latter step, 1.5 g/L of ²H,¹²C glucose was used, together with 1.5 g/L of ²H,¹⁵N-labeled Celtone base powder (Cambridge Isotope Laboratories Inc.) When the OD₆₀₀ reached 0.6, specific ¹H,¹⁴N,¹²C,¹³CO-labeled amino acids (as required) were added individually to the growth. The following amounts were used (depending on which specific amino acid was being selectively ¹³CO-labeled): Ala - 212 mg/L, Gly - 178 mg/L, Ile - 87 mg/L, Leu - 233 mg/L, Val - 125 mg/L. After 0.5 h of incubation in a shaker at 37°C, the cells were put on ice for 0.5 h, induced with 400 μM IPTG, and transferred into the shaking incubator at 17°C. After ~16 h of induction, selectively labeled amino acids were added to the growth in the amounts mentioned above. The cells were spun down and stored after growth for 24 h. In case of Leu and Val selective labeling, 250 mL of media were used for the final growth.

For purification, the cells were thawed on ice and resuspended in 20 mL of lysis buffer (50 mM Tris, pH 7.5, 750 mM NaCl, 0.5 % Triton, 0.1 % β-mercaptoethanol, 1 Roche protease inhibitor cocktail tablet), passed three times through a French pressure cell and centrifuged at 75000 g. The supernatant was then incubated with 5 mL of Co⁺² resin (TALON, Clontech) under gentle agitation at 4°C for 0.5 h, then loaded onto a column, washed multiple times, first with lysis buffer, then with wash buffer (50 mM Tris, 150 mM NaCl at pH 7.5), then again with wash buffer containing 3 mM imidazole, and finally eluted with wash buffer containing 200 mM imidazole. The protein was dialyzed against 20 mM Tris, 150 mM NaCl, 2.5 mM CaCl₂, 0.1% β-mercaptoethanol, pH 8.3, and the His₆ tag was cleaved using 2 units/mg of human α-thrombin (Enzyme Research Laboratories). The completeness of the cleavage was monitored using 20% SDS gels. Adding 200 mM AEBSF and 5 mM DTT stopped the cleavage reaction. The protein was concentrated using AMICON (Milipore) concentrators, and loaded onto a gel filtration column (Sephacryl S-100 HR) pre-equilibrated with the NMR buffer (50 mM phosphate, 150 mM NaCl, 2 mM DTT, 500 μM EDTA, pH 6.8). The concentration of ERK2 in the NMR samples was kept around 200 μM for greater stability.

NMR Experiments

All NMR spectra were recorded at 25°C. Typically ~200 μM inactive ERK2 in NMR buffer containing 10% D₂O was loaded into a 5 mm Shigemi tube susceptibility-matched to water. Spectra were collected at multiple fields (600 MHz, 700 MHz, 800 MHz and 900 MHz) on Bruker Avance spectrometers or on a Varian Inova operating at 600 MHz. All spectrometers were equipped with cryogenic probes capable of applying pulsed field gradients along the z-axis. Triple resonance experiments were collected both in the presence and absence of 10 mM MgCl₂ and 4 mM ADP. TROSY versions (37) of the following triple resonance experiments were collected: HNCO (800 MHz, with and without Mg⁺²/ADP), HNCACB (800 MHz, with Mg⁺²/ADP; 900 MHz, without Mg⁺²/ADP), HNCA (700 MHz, without Mg⁺²/ADP; 800 MHz, with Mg⁺²/ADP), HN(CO)CA (600 MHz with and without Mg⁺²/ADP) and HN(CA)CO (800 MHz, only for the Mg⁺²/ADP state). 3D ¹⁵N-edited NOESY-

TROSY experiments with mixing times of 120 ms, (600 MHz, no $\text{Mg}^{+2}/\text{ADP}$), 180 ms and 400 ms (800 MHz, with $\text{Mg}^{+2}/\text{ADP}$) were also collected. ^{15}N , ^1H TROSY and TROSY-based HNC0 experiments were also collected for each sample grown in the presence of specific ^{13}C -labeled amino acids (Leu, 800 MHz with $\text{Mg}^{+2}/\text{ADP}$; 700 MHz, without $\text{Mg}^{+2}/\text{ADP}$; Val 800 MHz, without $\text{Mg}^{+2}/\text{ADP}$; Ile, 900 MHz, without $\text{Mg}^{+2}/\text{ADP}$; Ala 800 MHz, with $\text{Mg}^{+2}/\text{ADP}$; Gly 600 MHz, with $\text{Mg}^{+2}/\text{ADP}$). Sub-stoichiometric amounts (1:0.25 or 1:0.5) of a spin-labeled ATP (sl-ATP) analog (that contained a mixture of species nitroxide-labeled at the ribose 3' 70%–80%, or the ribose 2' 20–30%, a kind gift from Dr. Pia D. Vogel) was added to a 200 μM ERK2 NMR sample containing 5 mM MgCl_2 (in NMR buffer prepared without DTT). ^{15}N , ^1H TROSY and TROSY-HNC0 experiments were recorded before and after addition of the sl-ATP and the effects of the spin-label were evaluated by analyzing the ratios of peak intensities. Drawbacks of using this simple approach for quantitative analyses of paramagnetic relaxation enhancement (PRE) effects have been noted (38), however, it is sufficient for our case since the PRE data was only used qualitatively. To aid the resonance assignment procedure, chemical shifts were predicted from the known crystal structures (PDB IDs: 1ERK and 3ERK) using the program Sparta (39) and manually corrected for ^2H isotope effects on ^{13}C chemical shifts (40). Details of the procedures used for resonance assignment will be described elsewhere (41).

Docking Interactions with Inactive ERK2

Chemical shift perturbations in inactive ERK2 in the presence of the following ERK2 ligands were analyzed:

- a. FQRKTLQRRNLKGLNLNL-(Δ)₃-TGPLSPGPF, an 18-residue peptide bearing a D-site sequence from the yeast MAPKK Ste-7 separated from a 9-residue substrate segment by chain consisting of three 6-aminohexanoic acid (Δ) spacers.
- b. A 17-residue peptide derived from the *N*-terminus of the transcription factor Elk-1 bearing a D-site sequence: QKGRKPRDLELPLSPSL.
- c. A construct consisting of the *N*-terminal 138 residues from the transcription factor Ets-1 (Ets-1 Δ 138, referred to as *Ets* for simplicity).
- d. The full-length 15 kDa adaptor protein PEA-15 (phosphoprotein enriched in astrocytes).

The synthesis of peptide (a) will be described elsewhere (Lee et al., manuscript in preparation). Peptide (b) was synthesized at the University of Texas Molecular Biology Core facilities. *Ets* (42) and PEA-15 (28) were expressed and purified as described earlier.

All NMR samples for the binding experiments were prepared in NMR buffer that did not contain Mg^{+2} or ADP. The ERK2 concentration was approximately 200 μM containing an excess of the specific unlabeled ligand (400 μM Ste-7 peptide, 500 μM Elk-1 peptide, 1 mM *Ets* and 1 mM PEA-15). For all samples, ^{15}N , ^1H -TROSY and TROSY-based HNC0 and HNCA (only for the Elk-1 peptide, *Ets* and PEA-15) experiments were recorded at 700, 800 or 900 MHz. Combined backbone chemical shift changes were evaluated using the formula given below, utilizing the chemical shift perturbations for $^{13}\text{C}^{i-1}$, $^{15}\text{N}^i$ and amide $^1\text{H}^i$ nuclei from a TROSY-based HNC0 experiment (see Supplementary Table S1):

$$\Delta\delta = \sqrt{(0.46 \Delta\delta_{^{13}\text{C}^{i-1}})^2 + (0.17 \Delta\delta_{^{15}\text{N}^i})^2 + (\Delta\delta_{^1\text{H}^i})^2}$$

Note that we relied on 3-dimensional TROSY-HNC0 spectra in the presence of saturating amounts of ligand rather than on 2-dimensional ^{15}N , ^1H TROSY experiments to evaluate

chemical shift perturbations. This was necessary due to the extensive spectral overlap that resulted in a limited number of residues that could be analyzed using 2-dimensional spectra. Nevertheless a representative example of a titration course using 2-dimensional spectra is shown in Supplementary Figure S1. These spectra illustrate the gradual change in chemical shift values in a ^{15}N , ^1H TROSY experiment in the presence of increasing amounts of ligand. Absolute values of the $^{13}\text{C}^\alpha$ chemical shift perturbations (see Supplementary Table S2) in the presence of the ligands were also measured using TROSY-based HNCA experiments. All spectra were processed using NMRpipe (43) and analyzed using Sparky (T. D. Goddard and D. G. Kneller, University of San Francisco).

Chemical shifts perturbations were deemed significant if exceeded an internal threshold (around 0.06 ppm for the two D-site peptides and *Ets*, and around 0.11 ppm for PEA-15) defined as the average perturbations plus twice the standard deviation calculated on a portion of the protein (typically the first 70 residues) not expected to participate in the binding interaction. To minimize possible perturbations induced by the buffer and temperature changes, the same buffer stock was used for all samples, and all instruments were temperature calibrated using methanol. The pH values of the samples were checked before and after addition of the peptides. It should be noted that the duplicate reference spectra collected at different times and at different spectrometer frequencies were highly superimposable, providing a control for the specific nature of the chemical shifts seen.

RESULTS

Using available structural information, spin-labeled ATP analogs, selectively labeled samples in addition to conventional backbone-directed resonance assignment strategies, a total of 89.4% of the ^1H , ^{15}N resonances that were observed at 800 MHz (65.1% of all expected resonances) were unambiguously assigned (see Figure 2). Of the regulatory elements conserved in protein kinases (10, 11), 81% of the regulatory helix αC , 100% of the Gly-rich loop and D165 of the DFG motif, were assigned. In addition, assignments were obtained for 62% of the C-spine and 50% of the R-spine (see Figure 1A). However, few assignments could be obtained for the αF helix (16%) and the catalytic and activation loops. The extent of ^1H , ^{15}N resonance assignment for the DRS was almost complete (95%) and partially complete for the FRS (46%, excluding the activation loop). The procedures used to achieve this level of resonance assignment for a system such as this is highly non-trivial and will be described at length elsewhere (41).

Having obtained a significant portion of the resonance assignments at the sites of protein-protein interactions involving ERK2, we focused on determining the chemical shift perturbations reflective of structural changes induced by a series of upstream and downstream regulators and targets that bear both canonical as well as non-canonical binding motifs. See Supplementary Tables S1 and S2 for numerical values of the chemical shift perturbations.

Binding of a Peptide Derived from the N-terminus of Ste-7 to Inactive ERK2

The MAPKK Ste-7 has been shown to interact with and phosphorylate Fus3, the yeast ortholog of ERK1/2 and this interaction plays a central role in the MAPK signal cascade that regulates mating signals in yeast (44). As our first target, we tested the structural perturbations induced by a peptide derived from the N-terminus of Ste-7 fused to a 9-residue substrate motif using three 6-aminohexanoic acid (Δ) spacers: $^2\text{FQRKTLQRRNLKGLNLNL}^{19}-(\Delta)_3\text{-TGPLSPGPF}$ (Ste-7 numbering shown). This conserved N-terminal motif has been shown to be sufficient to bind to ERK1 and ERK2 (45). This peptide contains a canonical D-site sequence $^9\text{RRX}_5^{15}\text{LXL}^{17}$ (where L15 and L17 correspond to the two D-site hydrophobic residues Φ_A and Φ_B respectively, binding is

abolished when these residues are mutated to Ala (45)). As expected, the peptide induces chemical shift perturbations localized in the DRS (see Figures 3A and 4A). In particular, several residues located on Loop 16 containing the Φ_{chg} sub-site, which include the charged residues D316, D319, E320, are affected by ligand binding. The Φ_{chg} sub-site interacts with the two charged residues, R9 and R10, located at the *N*-terminus of the D-site sequence. Charge reversal mutations, R9E and R10E, almost completely abolishes binding to ERK2 (45). Perturbations on the Φ_{hyd} sub-site (that hosts the hydrophobic Φ_{A} and Φ_{B} residues of the D-site) are localized on helix αE , Loop 8, helix αD and Loop 11. In this area, a number of hydrophobic residues including L113 and L155 are perturbed. Together with F127, these residues have been proposed to be critical for the recognition of the D-site sequence (F127 is unassigned, however neighboring Y126 is perturbed) (46). Further, perturbations are also observed on Loop 4, in the linker connecting the *N*- and the *C*-lobes and at the end of strand $\beta 5$ (Q103, the so-called gatekeeper residue, see below).

A superposition of the crystal structure of the Ste-7 peptide bound to Fus3 (22) onto the crystal structure of inactive ERK2 bound to a peptide derived from the tyrosine phosphatase HePTP (23) (See Figure 4C) suggests similarities between their binding modes. In the two kinases i.e. ERK2 and Fus3, the DRS appears to be both conserved both in sequence and in structure (i.e., upon superposition of the two domains, for residues within 6 Å from Ste-7 we observed 66.6% sequence identity and a heavy-atom RMSD of 0.57 Å) and both ligands appear to adopt a similar overall orientation in the binding pocket. Though the backbone arrangement of the two peptides is only approximately similar (they both share a similar L-shaped topology, with one segment recognizing the Φ_{chg} sub-site, and the second segment the Φ_{hyd} sub-site, with a Asn/Gln residue stabilizing the turn between these two segments), a number of key conserved side chains are spatially coincident, and their orientation is fully consistent with the observed chemical shift perturbations (see Figure 4C). In particular R9 on Ste-7 (R20 in HePTP) interacts with perturbed D319 on Loop 16 and E79 on Loop 4; R10 on Ste-7 (R21 in HePTP) interacts with perturbed D316 and E320 on Loop 16. L15 on Ste-7 (L27 in HePTP, residue Φ_{A} from the D-site) interacts with perturbed H123 and Y126, and L17 on Ste-7 (L29 in HePTP, Φ_{B}) is buried in a pocket including T108, L113, L155 and C159, all of which show significant chemical shift perturbations. The only long-range perturbation observed involves Q103, the gatekeeper residue, which has been suggested, to be allosterically coupled to the active site (47). This, together with the linker perturbations belonging to residues flanking the ATP binding pocket may explain the modest 1.3-fold change in the k_{cat} for the ERK2-catalyzed phosphorylation of an F-site-derived substrate, observed upon engaging of the DRS by the Ste-7 peptide (Lee et al. in preparation). It has been shown that docking interactions lead to significant conformational changes at the catalytic site and result in an active-like conformation (48). The *C*-terminal part of the peptide corresponding to a substrate sequence was not expected to interact with inactive ERK2, and indeed no other perturbations distant from the DRS can be seen in the *N*-lobe, although the catalytic and activation loops are largely unassigned. No significant perturbations were observed at the FRS.

Binding of a Peptide Derived from Elk-1 to Inactive ERK2

Next we investigated the binding of a D-site peptide derived from the transcription factor Elk-1 ($^{311}\text{QKGRKPRDLELPLSPSL}^{327}$ containing the canonical D-site sequence, $^{314}\text{RKX}_5\text{LXL}^{323}$), a member of the ETS family (9), that is a substrate for ERK2 (49). This peptide also induces significant chemical shift perturbations in the DRS (see Figure 3B and Figure 4B). Loop 16 (Φ_{chg} sub-site) is moderately affected; among others, the acidic residues E312, D316 and D319 display small but significant chemical shift changes. On Loop 4 small perturbations are observed for N80, but not for E79. On the Φ_{hyd} sub-site, perturbations are localized on helix αE and helix αD , only modest perturbations are seen for

Loop 8. Again, as in the case of Ste-7, the hydrophobic residues, L113, L155 and Y126 are affected by ligand binding. Perturbations are further observed on Loop 11 on the linker between the *N*- and *C*-lobes, and at the end of strand $\beta 5$ (Q103). In addition, in the presence of the Elk-1 derived peptide, a TROSY-based HNCA spectrum was also collected and the deviations of $^{13}\text{C}^\alpha$ chemical shift from the unbound state, which are particularly sensitive to changes in backbone secondary structure, were computed (see Figure 5A). Here, chemical shift perturbations are localized on helix αE , and, to a lesser extent, on helix αD and on the inter domain linker (see Supplementary Table S2).

The Φ_{chg} sub-site perturbations on the common docking residues D316 and D319 indicate that their side chains engage R4 and K5 on the *N*-terminal end of the Elk-1 peptide, however the lack of perturbations on E79 and E320 (that display perturbations for the Ste-7 peptide) suggests that the spatial arrangement of the basic residues in Elk-1 is somewhat different from that observed in the known crystal structures of ERK2-bound D-peptides (23, 48). This finding appears to be in contrast to the results of Zhang and coworkers who reported a modest 1.8-fold increase in the K_M for the E79A mutant (50). The architecture of Loop 4 is well conserved in all ERK2 crystal structures and the sidechain of E79 is part of an electrostatic network involving R133 and the acidic residues on Loop 16. It is therefore conceivable that the E79A mutation indirectly affects the K_M by somewhat altering the overall conformation of the kinase. The three-fold decrease in k_{cat} associated with the E79A mutant (50) would also be consistent with this scenario. The chemical shift perturbations observed for the backbone amide resonances of the hydrophobic residues of helices αE , αD and Loop 11 indicate that the interaction of L320 (Φ_A) and L322 (Φ_B) from the Elk-1 peptide with these hydrophobic clefts represents the other major determinant for Elk-1 binding.

In general, the very limited number of $^{13}\text{C}^\alpha$ perturbations (see Figure 5A) detected for ERK2 in the presence of Elk-1 confirms that the overall backbone architecture of the DRS does not change upon peptide binding. Interestingly however, the only significant changes in the $^{13}\text{C}^\alpha$ chemical shifts were also found in this area (H123 and Y126). This indicates that the insertion of the hydrophobic side chains from Elk-1 into the protein core does slightly affect the local conformation. In the crystal structures of ERK2 bound to peptidic ligands, the αE helix does not seem to undergo any significant conformational changes. It is however tempting to interpret the significant downfield shifts of the $^{13}\text{C}^\alpha$ resonances for H123 and Y126 as a consequence of an increased rigidity of the αE helix induced by the peptide binding. The remaining $^{13}\text{C}^\alpha$ perturbations are found on the linker between the *N*- and *C*-lobes. These perturbations, combined with those seen for the backbone amide resonances for $\beta 5$, indicate that binding of the Elk-1 peptide may alter the relative orientation of the *N*- and *C*-lobes. Lack of perturbations on or near the FRS confirmed the results obtained for the Ste-7 case and indicated that binding to the DRS by canonical D-site ligands does not have any significant effects on the FRS.

It is to be noted that a hydrogen exchange mass spectrometry (HXMS) study is available on the same peptide with active ERK2 (21). These results indicate the highest levels of protection for the αD and αE helices and Loop 11, in the presence of the Elk-1 peptide, in line with the nature of chemical shift perturbations seen here. Loop 16 bearing the Asp residues of the common docking motif whose chemical shifts are perturbed also experiences increased protection. Interestingly, Loop 4 (as reported by N80) that displays small chemical shift perturbations experienced decreased protection in the HXMS studies. The incompleteness of resonance assignment in the activation and catalytic loops prevented a comparison for this region. However, overall, the NMR and HXMS results are in agreement though some minor differences could be the result of differences between active (used in the HXMS studies) and inactive (used in the present study) ERK2.

Interactions of Ets-1 with Inactive ERK2

Having analyzed the structural perturbations induced by canonical D-site peptides, we focused our attention towards investigating the structural perturbations resulting from Ets-1 that belongs to the ETS family of transcription factors (9). Ets-1 is phosphorylated by ERK2 on T38 that lies on a consensus (Φ XS/TP, Φ is a hydrophobic residue) sequence. This residue lies in a disordered region at the *N*-terminal end of the α -helical pointed (PNT) (or SAM) domain of Ets-1 (51)Nelson, 2010 #47}. Ets-1 binds both active ERK2 and inactive ERK2, the latter believed to be incapable of fully recognizing the $^{36}\text{LXTP}^{39}$ sequence, (27), with comparable affinity. An overall similarity between the binding modes of Ets-1 on both the active and inactive forms of the enzyme has been suggested (15, 52). Interestingly, Ets-1 does not possess any canonical D- or F-sites and yet can be displaced by the D-site peptide from Elk-1 (discussed above) from inactive ERK2 (27). This suggests that Ets-1 utilizes the DRS to interact with inactive ERK2. Additionally, involvement of the FRS in Ets-1/ERK2 interactions has also been noted (27).

Binding of a construct consisting of the 138 *N*-terminal residues of Ets-1 (Ets-1 Δ 138, referred to as *Ets* for simplicity) to inactive ERK2 induces a number of perturbations on the surface of the latter (see Figure 3C and Figure 6A). A majority of these perturbations are localized on the Φ_{hyd} sub-site of the DRS (helix α E, α D, Loop 8 and on Loop 11) and again includes L113, L155 and Y126 (as in the case of the canonical D-site peptides from Elk-1 and Ste-7). No significant perturbations are observed on the charged residues on the Φ_{chg} sub-site, or on Loop 4. Other perturbations contiguous to the DRS are found on helix α F (N222), and on the *N*- to *C*-lobe linker. Long-range amide perturbations on the *N*-lobe are observed on strands β 1 (G30) and β 5 (Q103). Unlike in the case of the canonical D-site peptides, a second set of perturbations for main-chain amides, are seen at the FRS on helix α 2L14 in the MAPK insert and on helix α G. Most notably, significant perturbations are seen for Y261 and its flanking residues. This residue has been shown to be crucial in binding canonical F-site peptides and is a crucial component of the FRS (21). On the MAPK insert, the disappearance of the resonance corresponding to L250 on helix α 1L14, which is not part of the canonical FRS site (see Figure 1 and Supplementary Figure S2), was observed. It should be noted that assignments are not available for all residues that constitute the FRS (see Supplementary Figure S2), however a large number of FRS residues for which assignments are available do show chemical shift changes (see Figure 3C, Figure 6A and Supplementary Figure S2) in the presence of *Ets*. As discussed earlier, no resonance assignments are available for the part of helix α G that bears the residues Y231 and L232 (see Supplementary Figure S2) that have also been shown to be involved in formation of the FRS (21). However cysteine foot-printing studies reveal that position 232 shows a 3.5-fold higher protection against cysteine alkylation in the presence of *Ets* than in its absence (see Supplementary Figure S3). This, in combination with our NMR results, suggests that a large part of the FRS is indeed involved in recognizing *Ets*. The magnitude of the $^{13}\text{C}^{\alpha}$ perturbations (see Figure 5B) is reduced compared to that seen for the Elk-1 peptide (however H123 that undergoes the largest shift in the $^{13}\text{C}^{\alpha}$ resonance position in the case of the Elk-1 peptide was severely broadened and could not be assigned in the presence of *Ets*). Most of the $^{13}\text{C}^{\alpha}$ perturbations are seen on Loop 8 and on helix α D, weak perturbations are also localized on the MAPK insert (see Supplementary Table S2).

The NMR data indicate that *Ets* binding to inactive ERK2 involves both the DRS and at least part of the FRS. This indeed is consistent with the proposed binding model for active ERK2 where *Ets* engages the ERK2 DRS using its flexible *N*-terminal extension, and the PNT domain recognizes a binding pocket (part of the FRS) composed of α 2L14 on the MAPK insert, the α G helix and the end of the activation loop (15) (also see Supplementary Figure S4). Indeed, an Ets-1 construct consisting of only the PNT domain (residues 51–138) binds ERK2 with a 20-fold reduced affinity and a construct that contains only the flexible *N*-

terminus (residues 1–52) binds ERK2 with a 4-fold reduced affinity (15). Site-directed mutations in the PNT domain also implicate it in interactions with ERK2 (53). The lack of perturbations on the Φ_{chg} sub-site as well as on Loop 4 indicate that electrostatic interactions, typically involving basic residues on the *N*-terminal portion of the DRS binding peptide, do not play an appreciable role here. Our data suggest that hydrophobic interactions at the Φ_{hyd} sub-site are primarily responsible for the binding of *Ets* at the DRS. The extent of the perturbations, involving helix αE , αD Loop 8 and Loop 11, indicates that the hydrophobic pocket is fully recognized, which normally requires the insertion of at least two hydrophobic side chains from the ligand. Modeling studies (see Supplementary Figure S4, (52)) suggest that three hydrophobic residues from the flexible *N*-terminal extension of *Ets*, namely L11, I13 and I14 may engage the Φ_{hyd} sub-site of the DRS. Interestingly, a mutation of the αE residue H123 to Ala leads to the largest increase in K_{M} for *Ets* phosphorylation by ERK2, whereas the double mutation D316A/D319A (common docking Asp residues on Φ_{chg}) had little effect on K_{M} (29). On the *Ets* side, L11 that is suggested to occupy the pocket generated by H123 and Y126 (usually occupied by Φ_{A} residue on a canonical D-site) on ERK2 when mutated to Asp leads to a 3-fold increase in K_{M} with no observation change in k_{cat} (52). A I13D/I14D double mutation leads to similar effects suggesting a role for these hydrophobic residues in the *Ets*/ERK2 interaction.

Chemical shift perturbations of the main-chain amides at the FRS, previously undetected for the D-site ligands, indicate that this site, which is remote from the DRS, is also involved in the *Ets* recognition process. The relatively modest $^{13}\text{C}^{\alpha}$ perturbations show that *Ets* binding does not introduce large structural changes in the kinase, with some local structural rearrangement localized on the Φ_{hyd} subsite. Chemical shift perturbations on the linker between the *N*- and *C*-lobe linker and for the *N*-lobe itself are indicative of some long-range effects, but they do not differ significantly from those induced by the D-site ligands discussed above.

Binding of Full-length PEA-15 to Inactive ERK2

The adaptor protein PEA-15 has been shown to regulate the cellular localization of ERK2. It has been shown to associate specifically with ERK2 but not the homologous MAPK p38, blocking ERK2 dependent transcription by preventing its translocation to the nucleus (54). PEA-15 has an all α -helical death-effector domain fold (DED) with a disordered *C*-terminus (55). NMR and mutational analyses have revealed a direct and specific interaction of inactive ERK2 with PEA-15 involving both the *C*-terminus and the DED of the latter (55). The *C*-terminus has been predicted to bind the DRS of ERK2 (28). It is therefore only logical to investigate the structural perturbations induced by PEA-15 on ERK2 using NMR chemical shift mapping. The overall pattern of chemical shift perturbations seen is similar in location to that observed for *Ets* (see Figure 4D and Figure 6B), although the magnitude of the perturbations is greater by a factor of around two. As in *Ets*, Loop 16 is poorly perturbed, with the only noticeable difference being the perturbation of the common docking D316, in addition to Y314, though these perturbations are quite small in comparison to others seen in the presence of PEA-15. A weak but detectable perturbation is also found for N80 on Loop 4. Again, the largest variations are localized on helix αE on helix αD , on Loop 8 and on Loop 11. Perturbations are also found at the end of helix αF , and on the *N*- to *C*-lobe linker. At the FRS, all segments for which resonance assignments are available including portions of helix αG as well as helix α2L14 (including Y261) exhibit appreciable perturbations. However, in contrast to *Ets*, PEA-15 also induces strong perturbations on helix α1L14 (see Figure 6).

As in the case of the Elk-1 peptide, the largest perturbations in $^{13}\text{C}^{\alpha}$ chemical shifts (see Figure 5C) are seen for H123 and Y126 on αE , but in this case, detectable $^{13}\text{C}^{\alpha}$ perturbations are widespread on the DRS (Loop 11, helix αD and Loop 8) and on the MAPK

insert (helices $\alpha 2L14$ and $\alpha 1L14$). The interactions detected for D316 and Loop 4 suggest an involvement of electrostatic interactions in stabilizing the ligand at the DRS site. However, these perturbations are few and weak, and therefore, as is the case for *Ets*, it seems that PEA-15 mainly recognizes the DRS through hydrophobic interactions involving the Φ_{hyd} sub-site. As mentioned in the case of *Ets* earlier, these interactions are likely to require at least two hydrophobic side chains (as in *Ets* discussed earlier) of the ligand. Based on the data of Hill et al. (55) we hypothesize that these are likely to be I121 and L123. Mutation of these residues abolishes the PEA-15/ERK2 interaction *in vitro* and also suppresses ERK2 dependent transcriptional activity *in vivo* (55).

The influence of several FRS residues of ERK2 on PEA-15 binding has been assessed through extensive site-directed mutagenesis. Most notably the mutations K257E and R259E (14) (for which assignments are not available but lie in close proximity to Y261 and L262 which show extremely large perturbations, see Supplementary Table S1) greatly reduced PEA-15 binding. All of these residues lie on $\alpha 2L14$ suggesting its direct role in recognizing PEA-15. In addition, K229 and Y231 (on αG , for which assignments are not available) also seem to play a substantial role in PEA-15 binding (14). This role is confirmed by the 110-fold greater protection from Cys alkylation at position 232 in the presence of PEA-15 (28). Large chemical perturbations are also seen in helix $\alpha 1L14$ (see Supplementary Table S1 and Figure S2) that is not considered to be a part of the FRS. Mutation of N251 (that also shows significant chemical shift perturbations) does not significantly affect PEA-15 binding (14). Though additional mutational data is required to confirm its role, it seems that $\alpha 1L14$ likely plays an indirect role in PEA-15 binding.

From $^{13}C^{\alpha}$ perturbations, it appears that PEA-15 affects the local conformation of ERK2 more than any other ligand examined by us so far. As seen for the Elk-1 derived peptide, the largest $^{13}C^{\alpha}$ perturbations are located at the Φ_{hyd} sub-site (see Figure 5C), and especially for H123 and Y126, but several other perturbations can be found at the FRS and on several flexible regions, including the N- to C-lobe linker. This suggests substantial local conformational rearrangements in ERK2 upon interactions with PEA-15.

DISCUSSION

Docking interactions represent a key mechanism to affect cellular signaling involving MAP kinases, as they mediate the formation of regulatory complexes and modulate the specificity and the efficiency of all the catalytic processes involving up-regulating kinases, down-regulating phosphatases and downstream substrates (17). Among the large number of substrates and regulatory proteins targeting the ERK2 docking sites, there are currently only two crystal structures that illustrate docking interactions involving ERK2, and in both cases ERK2 is bound at the DRS to peptides derived from protein phosphatases, namely HePTP (48) and MKP3 (23). While no direct crystallographic information is available for an F-site ligand bound at the FRS, HXMS data coupled with site-directed mutagenesis has provided insight into the nature of this site and key residues that constitute it (21). For interactions that do not employ canonical D-site or F-site sequences, a number of studies have already appeared in literature aimed at mapping the ERK2 binding surfaces using biochemical techniques (15, 27–29) though no direct structural information exists. These studies involve the use of site directed mutagenesis to evaluate the role of a particular residue in ligand binding (K_M or K_D) or in kinetic efficiency (k_{cat}/K_M). Another approach that has been used to examine ERK2 utilizes cysteine foot-printing, where a cysteine mutation is inserted into the surface of interest, and its rate of alkylation is measured in the presence and absence of ligands (29). Unlike the techniques described above, NMR is a biophysical method that allows comprehensive monitoring of the effects of ligand binding on the entire protein, without the need to mutate, or chemically modify the interacting partners. For the present

study we have utilized two peptide ligands derived from Ste-7 (a yeast ortholog of the up-regulating MAPKK) and from Elk-1 (an ERK2 substrate), both binding inactive ERK2 in the μM range (27) and both bearing canonical MAPK docking motifs (D-sites). The role of non-canonical interactions involving ERK2 has also been tested, utilizing an *N*-terminal construct from an ERK2 substrate, the transcription factor Ets-1 and the anti-apoptotic adaptor protein PEA-15, both of which bind inactive ERK2 with μM affinity. Our studies not only demonstrate the feasibility of investigating docking interactions involving a full-length ERK/MAP kinase using solution NMR methodology, but also provide considerable insight into the nature of these interactions including those for which no direct structural evidence is available.

Comparing different ligands that employ the D-site allows a clearer understanding of the recognition mechanism employed by the DRS. We find that for canonical D-site interactions, each particular ligand induces a discrete sets of chemical shift perturbations on the DRS surface, which suggests that the DRS surface is quite rigid. If it were not, a more uniform distribution of the perturbations across the DRS would be observed upon ligand binding. This overall rigidity and lack of any major changes in backbone conformation is also borne out by the limited number of $^{13}\text{C}^\alpha$ chemical shift perturbations seen in this region. On the other hand, this observation also indicates that the DRS is also promiscuous, seemingly employing slightly different recognition modes for the two ligands, and this is particularly evident at the Φ_{chg} sub-site. For example, as pointed out earlier, the binding mode of the Ste-7 peptide appears to be similar to that observed for the Ste-7/Fus3 crystal structure (22), and involves a number of charged residues on Loops 4 and 16. The Elk-1 peptide, on the other hand, also engages the Φ_{chg} sub-site, but some of the perturbations observed for Ste-7 (for instance, E320 on Loop 16, or E79 on Loop 4) are not seen, indicating a different pattern of electrostatic interactions (note that there are no crystal structures of ERK2 in complex with either the Elk-1 or the Ste-7 peptides). Elucidation of these residue-by-residue differences is a unique strength of atomistic techniques such as NMR, and cannot be easily obtained from fragment-based approaches such as HXMS.

In contrast to the Φ_{chg} sub-site, the Φ_{hyd} sub-site reveals large chemical shift perturbations in both the canonical (Ste-7, Elk-1) as well as the non-canonical (Ets-1, PEA-15) cases. These perturbations are consistently localized on helix αE , helix αD and Loop 11. This is also where $^{13}\text{C}^\alpha$ perturbations can primarily be found. Our data are consistent with the idea that the Φ_{chg} sub-site interactions consist of electrostatic contacts originating from charge-charge interactions between side-chains located on the protein surface, and have little effect on backbone architecture. The interactions hosted by the Φ_{hyd} sub-site, on the other hand, involve the insertion of hydrophobic side-chains of the ligand into the hydrophobic core of the protein, and therefore likely induce significant conformational changes in the affected area, including the backbone. Interestingly, the Loop 16 residue Y314, whose side chain is positioned between the two sub-sites, is also consistently perturbed. Some variation in the pattern of chemical shift perturbations can also be found at the Φ_{hyd} sub-site. For instance, L155 (Loop 11) is poorly perturbed in *Ets* with respect to the other ligands; the $^{13}\text{C}^\alpha$ chemical shift of Y126 (Helix αE) does not undergo major changes in the presence of *Ets*, as found for the Elk-1 peptide and PEA-15; K115 (Loop 8) does not seem to be affected by PEA-15 binding but displays significant perturbations in all other cases. Thus, it appears that the DRS can accommodate both canonical and non-canonical ligands mostly through the Φ_{hyd} sub-site. Therefore, this site should likely be the target of universal inhibitors of the docking interactions that target the DRS. Given the nature of residues in the disordered ends of *Ets* (*N*-terminal) and PEA-15 (*C*-terminal) that are suggested to engage the Φ_{hyd} sub-site, it can be speculated that the hydrophobic residues (L11, I13/I14 on *Ets* and I121, L123 on PEA-15) may perhaps substitute for the hydrophobic part i.e. $\Phi_{\text{A}}\text{-X-}\Phi_{\text{B}}$ of a canonical D-site.

Interactions involving the Φ_{chg} sub-site, on the other hand, does not seem to be a strict requirement for the non-canonical ligands that also utilize the DRS. *Ets* interacts poorly with this sub-site, inducing no perturbations for the two common docking Asp residues in ERK2. Only a weak perturbation can be found on D316, in the presence of PEA-15. Thus, small molecule inhibitors designed to disrupt interactions involving the Φ_{chg} site are likely to be more effective against ligands that employ canonical D-site sequences that more effectively use the Φ_{chg} region. Interestingly a mutational analysis indicates that the basic residues on the C-terminal tail of PEA-15 (K128, K129) are necessary for binding (55). However, the present studies seem to suggest that these charge interactions are less likely to involve the Φ_{chg} region of the DRS. It is also conceivable however, as noted above, that these interactions primarily involving side-chain moieties are weak enough to only mildly perturb the backbone.

For all ligands tested, in addition to the involvement of the DRS, we consistently detected perturbations on the linker between the *N*- and *C*-lobes, and on the $\beta 5$ strand, which constitutes part of the ATP binding pocket. This suggests a slight change in the overall orientation between the two lobes along with a remodeling of the catalytic site. The role of inter-lobe communications and relative orientation between the *N*- and *C*-lobes upon interactions involving the DRS in activation of MAP kinases has been demonstrated in the homologous Fus3 and JNK1 kinases upon docking interactions with Ste-5 (56) and Jip1 (57) respectively. For ERK2 as well, the flexibility of the linker and the change of the relative orientation of the *N*- and *C*-lobes upon activation have been demonstrated by HXMS studies (58). In all the cases we analyzed (except for PEA-15) in the present study, Q103, the gatekeeper residue that lies on the $\beta 5$ strand, is consistently perturbed upon binding of the substrates. Mutation of this residue to Ala or Gly leads to weak constitutive activation of ERK2 through intra-molecular auto-phosphorylation, suggesting that this residue is dynamically coupled to the active site (47). This information coupled with our current results is suggestive of an allosteric network involving the DRS and the active site, coupled through the gatekeeper. Importantly, we did not observe any effects on the FRS upon binding of the two D-site ligands that specifically target the DRS, suggesting that these two recruitment sites are uncoupled from each other.

In contrast to the D-site peptides, *Ets* and PEA-15 also induce perturbations on a second binding pocket formed by the MAPK insert and helix αG . Therefore these data support our previously proposed model (15, 52) where both *Ets* and PEA-15 bind ERK2 in a bi-dentate fashion, the folded domain (PNT and DED, respectively) recognizes the FRS, and the flexible extension folds around the ERK2 surface and bind the DRS (15) (also see Supplementary Figure S4, (52)). The overall pattern of chemical shift perturbations observed in inactive ERK2 upon binding of both *Ets* and PEA-15 is strikingly similar though larger chemical shift perturbations are seen for PEA-15 than *Ets*. In particular for PEA-15, larger and more extensive perturbations are observed for helix αG and also for the MAPK insert where the perturbations involve both helices $\alpha 1 L14$ and $\alpha 2 L14$. This may suggest a slight difference in the modes with which PEA-15 and *Ets* engage ERK2 and/or these ligands induce unique conformational changes in ERK2. It should be noticed that, for active ERK2, although *Ets* is displaced by peptides that bind the F-site, PEA-15 is not (27, 28), which would be consistent with our hypothesis.

CONCLUSIONS

The studies presented here represent a first step in utilizing the range of information that solution state NMR spectroscopy can provide, for interactions involving ERK/MAP kinases. Our present analysis, based on chemical shift perturbations on inactive ERK2 induced by a range of ligands that employ canonical and non-canonical docking motifs, highlights the

similarities and differences between these interactions. Canonical D-site peptides rely on both charge-charge as well as hydrophobic interactions to dock onto ERK2. Non-canonical ligands such as Ets-1 and PEA-15 primarily utilize hydrophobic interactions. These findings are in agreement with mutational and functional studies and also with results from HXMS studies, where available. We also confirmed the results of prior biochemical and mutational studies that the aforementioned non-canonical ligands utilize two distinct docking sites for ERK2 recognition, probably as a way to achieve higher selectivity (in the case of a substrate like Ets-1) or more effective inhibition (in the case of the regulator PEA-15). Our work seems to indicate that these docking sites are not allosterically coupled and are targeted independently by the ligands through two distinct binding motifs.

During the preparation of this manuscript, an initial NMR analysis of D-site interactions in the MAPK p38 α appeared in the literature (34). This study employed a single D-site peptide derived from MEK3b and utilized 133 backbone amide chemical shifts of p38 α (that could be transferred from the original assignments of Vogtherr et al. (33) representing 37% coverage) as probes of structural changes upon binding. The results of that study are in general consistent with our results for the D-site peptides. However, only when multiple D-site ligands are employed, as in the present work, the subtle differences characterizing the modes of D-site peptide recognition by ERK/MAP kinases become evident. Nevertheless, it would be extremely useful to obtain further dynamic and structural details of D-site interactions involving both the ERK and the p38 sub-families, and perhaps others such as the JNKs (59). As far as non-canonical interactions are concerned, these have been characterized biochemically to a larger extent in ERK2, so at this stage ERK2 represents a more fruitful target for NMR and other biophysical studies.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The authors thank Dr. Pia D. Vogel, Southern Methodist University for a kind gift of the si-ATP. The authors also thank Dr. Mark Girvin (Albert Einstein College of Medicine) for useful discussions.

Abbreviations

MAP kinase	mitogen activated protein kinase
DRS	D-recruitment site
ERK	extracellular signal regulated kinase
DEF	docking site for ERK FXFP
DTT	dithio-threitol
EDTA	ethylenediaminetetraacetic acid
Ets	a construct of Ets-1 containing the N-terminal 138 residues
FRS	F-recruitment site
HXMS	hydrogen exchange mass spectroscopy
IPTG	isopropyl β -D-thiogalactopyranoside
MAPKK	mitogen activated protein kinase kinase
PEA-15	phosphoprotein enriched in astrocytes 15 kDa

References

1. Murphy LO, Blenis J. MAPK signal specificity: the right place at the right time. *Trends Biochem Sci.* 2006; 31:268–275. [PubMed: 16603362]
2. Chen Z, Gibson TB, Robinson F, Silvestro L, Pearson G, Xu B, Wright A, Vanderbilt C, Cobb MH. MAP kinases. *Chem Rev.* 2001; 101:2449–2476. [PubMed: 11749383]
3. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, Cobb MH. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. *Endocrine Rev.* 2001; 22:153–183. [PubMed: 11294822]
4. Fang JY, Richardson BC. The MAPK signalling pathways and colorectal cancer. *The Lancet Oncol.* 2005; 6:322–327.
5. Kohno M, Pouyssegur J. Targeting the ERK signaling pathway in cancer therapy. *Annals Med.* 2006; 38:200–211.
6. Kohno M, Pouyssegur J. Pharmacological inhibitors of the ERK signaling pathway: application as anticancer drugs. *Prog Cell Cyc Res.* 2003; 5:219–224.
7. Dalby KN, Morrice N, Caudwell FB, Avruch J, Cohen P. Identification of regulatory phosphorylation sites in mitogen-activated protein kinase (MAPK)-activated protein kinase-1a/p90rsk that are inducible by MAPK. *J Biol Chem.* 1998; 273:1496–1505. [PubMed: 9430688]
8. Roux PP, Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. *Microbiol Mol Biol Rev.* 2004; 68:320–344. [PubMed: 15187187]
9. Sharrocks AD. The ETS-domain transcription factor family. *Nature Rev Mol Cell Biol.* 2001; 2:827–837. [PubMed: 11715049]
10. Kornev AP, Taylor SS. Defining the conserved internal architecture of a protein kinase. *Biochim Biophys Acta.* 2010; 1804:440–444. [PubMed: 19879387]
11. Taylor SS, Kornev AP. Protein kinases: evolution of dynamic regulatory proteins. *Trends Biochem Sci.* 2011; 36:65–77. [PubMed: 20971646]
12. Parsons SJ, Parsons JT. Src family kinases, key regulators of signal transduction. *Oncogene.* 2004; 23:7906–7909. [PubMed: 15489908]
13. Robinson FL, Whitehurst AW, Raman M, Cobb MH. Identification of novel point mutations in ERK2 that selectively disrupt binding to MEK1. *J Biol Chem.* 2002; 277:14844–14852. [PubMed: 11823456]
14. Chou FL, Hill JM, Hsieh JC, Pouyssegur J, Brunet A, Glading A, Uberall F, Ramos JW, Werner MH, Ginsberg MH. PEA-15 binding to ERK1/2 MAPKs is required for its modulation of integrin activation. *J Biol Chem.* 2003; 278:52587–52597. [PubMed: 14506247]
15. Callaway K, Waas WF, Rainey MA, Ren P, Dalby KN. Phosphorylation of the transcription factor Ets-1 by ERK2: rapid dissociation of ADP and phospho-Ets-1. *Biochemistry.* 2010; 49:3619–3630. [PubMed: 20361728]
16. Sharrocks AD, Yang SH, Galanis A. Docking domains and substrate-specificity determination for MAP kinases. *Trends Biochem Sci.* 2000; 25:448–453. [PubMed: 10973059]
17. Remenyi A, Good MC, Lim WA. Docking interactions in protein kinase and phosphatase networks. *Curr Opin Struct Biol.* 2006; 16:676–685. [PubMed: 17079133]
18. Gavin AC, Nebreda AR. A MAP kinase docking site is required for phosphorylation and activation of p90(rsk)/MAPKAP kinase-1. *Curr Biol.* 1999; 9:281–284. [PubMed: 10074458]
19. Akella R, Moon TM, Goldsmith EJ. Unique MAP Kinase binding sites. *Biochim Biophys Acta.* 2008; 1784:48–55. [PubMed: 18068683]
20. Tanoue T, Adachi M, Moriguchi T, Nishida E. A conserved docking motif in MAP kinases common to substrates, activators and regulators. *Nature Cell Biol.* 2000; 2:110–116. [PubMed: 10655591]
21. Lee T, Hoofnagle AN, Kabuyama Y, Stroud J, Min X, Goldsmith EJ, Chen L, Resing KA, Ahn NG. Docking motif interactions in MAP kinases revealed by hydrogen exchange mass spectrometry. *Mol Cell.* 2004; 14:43–55. [PubMed: 15068802]
22. Remenyi A, Good MC, Bhattacharyya RP, Lim WA. The role of docking interactions in mediating signaling input, output, and discrimination in the yeast MAPK network. *Mol Cell.* 2005; 20:951–962. [PubMed: 16364919]

23. Liu S, Sun JP, Zhou B, Zhang ZY. Structural basis of docking interactions between ERK2 and MAP kinase phosphatase 3. *Proc Natl Acad Sci USA*. 2006; 103:5326–5331. [PubMed: 16567630]
24. Zhou B, Wang ZX, Zhao Y, Brautigan DL, Zhang ZY. The specificity of extracellular signal-regulated kinase 2 dephosphorylation by protein phosphatases. *J Biol Chem*. 2002; 277:31818–31825. [PubMed: 12082107]
25. Shi Z, Resing KA, Ahn NG. Networks for the allosteric control of protein kinases. *Curr Opin Struct Biol*. 2006; 16:686–692. [PubMed: 17085044]
26. Sheridan DL, Kong Y, Parker SA, Dalby KN, Turk BE. Substrate discrimination among mitogen-activated protein kinases through distinct docking sequence motifs. *J Biol Chem*. 2008; 283:19511–19520. [PubMed: 18482985]
27. Callaway KA, Rainey MA, Riggs AF, Abramczyk O, Dalby KN. Properties and regulation of a transiently assembled ERK2. Ets-1 signaling complex. *Biochemistry*. 2006; 45:13719–13733. [PubMed: 17105191]
28. Callaway K, Abramczyk O, Martin L, Dalby KN. The anti-apoptotic protein PEA-15 is a tight binding inhibitor of ERK1 and ERK2, which blocks docking interactions at the D-recruitment site. *Biochemistry*. 2007; 46:9187–9198. [PubMed: 17658892]
29. Abramczyk O, Rainey MA, Barnes R, Martin L, Dalby KN. Expanding the repertoire of an ERK2 recruitment site: cysteine footprinting identifies the D-recruitment site as a mediator of Ets-1 binding. *Biochemistry*. 2007; 46:9174–9186. [PubMed: 17658891]
30. Masterson LR, Cheng C, Yu T, Tonelli M, Kornev A, Taylor SS, Veglia G. Dynamics connect substrate recognition to catalysis in protein kinase A. *Nature Chem Biol*. 2010; 6:821–828. [PubMed: 20890288]
31. Masterson LR, Mascioni A, Traaseth NJ, Taylor SS, Veglia G. Allosteric cooperativity in protein kinase A. *Proc Natl Acad Sci USA*. 2008; 105:506–511. [PubMed: 18178622]
32. Vajpai N, Strauss A, Fendrich G, Cowan-Jacob SW, Manley PW, Grzesiek S, Jahnke W. Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib. *J Biol Chem*. 2008; 283:18292–18302. [PubMed: 18434310]
33. Vogtherr M, Saxena K, Hoelder S, Grimme S, Betz M, Schieborr U, Pescatore B, Robin M, Delarbre L, Langer T, Wendt KU, Schwalbe H. NMR characterization of kinase p38 dynamics in free and ligand-bound forms. *Angew Chem Int Ed Engl*. 2006; 45:993–997. [PubMed: 16374788]
34. Akella R, Min X, Wu Q, Gardner KH, Goldsmith EJ. The Third Conformation of p38alpha MAP Kinase Observed in Phosphorylated p38alpha and in Solution. *Structure*. 2010; 18:1571–1578. [PubMed: 21134636]
35. Wiesner S, Wybenga-Groot LE, Warner N, Lin H, Pawson T, Forman-Kay JD, Sicheri F. A change in conformational dynamics underlies the activation of Eph receptor tyrosine kinases. *EMBO J*. 2006; 25:4686–4696. [PubMed: 16977320]
36. Takeuchi K, Ng E, Malia TJ, Wagner G. 1-¹³C amino acid selective labeling in a 2H15N background for NMR studies of large proteins. *J Biomol NMR*. 2007; 38:89–98. [PubMed: 17390105]
37. Salzmann M, Pervushin K, Wider G, Senn H, Wuthrich K. TROSY in triple-resonance experiments: new perspectives for sequential NMR assignment of large proteins. *Proc Natl Acad Sci USA*. 1998; 95:13585–13590. [PubMed: 9811843]
38. Clore GM, Iwahara J. Theory, practice, and applications of paramagnetic relaxation enhancement for the characterization of transient low-population states of biological macromolecules and their complexes. *Chem Rev*. 2009; 109:4108–4139. [PubMed: 19522502]
39. Shen Y, Bax A. Protein backbone chemical shifts predicted from searching a database for torsion angle and sequence homology. *J Biomol NMR*. 2007; 38:289–302. [PubMed: 17610132]
40. Venters RA, Farmer BT 2nd, Fierke CA, Spicer LD. Characterizing the use of perdeuteration in NMR studies of large proteins: ¹³C, ¹⁵N and ¹H assignments of human carbonic anhydrase II. *J Mol Biol*. 1996; 264:1101–1116. [PubMed: 9000633]
41. Piserchio A, Dalby KN, Ghose R. Assignment of Backbone Resonances in a Eukaryotic Protein Kinase – ERK2 as an Illustrative Example. *Meth Mol Biol*. 2011 in press.

42. Waas WF, Dalby KN. Purification of a model substrate for transcription factor phosphorylation by ERK2. *Protein Expr Purif.* 2001; 23:191–197. [PubMed: 11570862]
43. Delaglio F, Grzesiek S, Vuister GW, Zhu G, Pfeifer J, Bax A. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. *J Biomol NMR.* 1995; 6:277–293. [PubMed: 8520220]
44. Posas F, Takekawa M, Saito H. Signal transduction by MAP kinase cascades in budding yeast. *Curr Opin Microbiol.* 1998; 1:175–182. [PubMed: 10066475]
45. Bardwell AJ, Flatauer LJ, Matsukuma K, Thorner J, Bardwell L. A conserved docking site in MEKs mediates high-affinity binding to MAP kinases and cooperates with a scaffold protein to enhance signal transmission. *J Biol Chem.* 2001; 276:10374–10386. [PubMed: 11134045]
46. Balasu MC, Spiridon LN, Miron S, Craescu CT, Scheidig AJ, Petrescu AJ, Szedlaczek SE. Interface analysis of the complex between ERK2 and PTP-SL. *PLoS One.* 2009; 4:e5432. [PubMed: 19424502]
47. Emrick MA, Lee T, Starkey PJ, Mumby MC, Resing KA, Ahn NG. The gatekeeper residue controls autoactivation of ERK2 via a pathway of intramolecular connectivity. *Proc Natl Acad Sci USA.* 2006; 103:18101–18106. [PubMed: 17114285]
48. Zhou T, Sun L, Humphreys J, Goldsmith EJ. Docking interactions induce exposure of activation loop in the MAP kinase ERK2. *Structure.* 2006; 14:1011–1019. [PubMed: 16765894]
49. Yang SH, Whitmarsh AJ, Davis RJ, Sharrocks AD. Differential targeting of MAP kinases to the ETS-domain transcription factor Elk-1. *EMBO J.* 1998; 17:1740–1749. [PubMed: 9501095]
50. Zhang J, Zhou B, Zheng CF, Zhang ZY. A bipartite mechanism for ERK2 recognition by its cognate regulators and substrates. *J Biol Chem.* 2003; 278:29901–29912. [PubMed: 12754209]
51. Slupsky CM, Gentile LN, Donaldson LW, Mackereth CD, Seidel JJ, Graves BJ, McIntosh LP. Structure of the Ets-1 pointed domain and mitogen-activated protein kinase phosphorylation site. *Proc Natl Acad Sci USA.* 1998; 95:12129–12134. [PubMed: 9770451]
52. Lee S, Warthaka M, Yan C, Kaoud T, Piserchio A, Ghose R, Ren P, Dalby KN. A model of a MAPK-substrate complex in an active conformation: a computational and experimental approach. *PLoS One* in press. 2011
53. Seidel JJ, Graves BJ. An ERK2 docking site in the Pointed domain distinguishes a subset of ETS transcription factors. *Genes Dev.* 2002; 16:127–137. [PubMed: 11782450]
54. Formstecher E, Ramos JW, Fauquet M, Calderwood DA, Hsieh JC, Canton B, Nguyen XT, Barnier JV, Camonis J, Ginsberg MH, Chneiweiss H. PEA-15 mediates cytoplasmic sequestration of ERK MAP kinase. *Dev Cell.* 2001; 1:239–250. [PubMed: 11702783]
55. Hill JM, Vaidyanathan H, Ramos JW, Ginsberg MH, Werner MH. Recognition of ERK MAP kinase by PEA-15 reveals a common docking site within the death domain and death effector domain. *EMBO J.* 2002; 21:6494–6504. [PubMed: 12456656]
56. Bhattacharyya RP, Remenyi A, Good MC, Bashor CJ, Falick AM, Lim WA. The Ste5 scaffold allosterically modulates signaling output of the yeast mating pathway. *Science.* 2006; 311:822–826. [PubMed: 16424299]
57. Heo YS, Kim SK, Seo CI, Kim YK, Sung BJ, Lee HS, Lee JI, Park SY, Kim JH, Hwang KY, Hyun YL, Jeon YH, Ro S, Cho JM, Lee TG, Yang CH. Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125. *EMBO J.* 2004; 23:2185–2195. [PubMed: 15141161]
58. Hoofnagle AN, Resing KA, Goldsmith EJ, Ahn NG. Changes in protein conformational mobility upon activation of extracellular regulated protein kinase-2 as detected by hydrogen exchange. *Proc Natl Acad Sci USA.* 2001; 98:956–961. [PubMed: 11158577]
59. Davis RJ. Signal transduction by the JNK group of MAP kinases. *Cell.* 2000; 103:239–252. [PubMed: 11057897]

Figure 1.

Ribbon representation of the structure of ERK2. **(A)** The *N*- and *C*-lobes are colored gold and light green respectively. The MAP kinase insert is colored gold and the *C*-terminal helix is colored green. The activation loop bearing the catalytic T183 and Y185 (indicated in stick representation) is colored magenta. The so-called R- and C-spines are shown as surfaces and colored red and blue respectively. These two spines rest on the α F helix, which, along with other key helices, is labeled. **(B)** The D-recruitment site (DRS) and the F-recruitment site (FRS) are shown. The FRS is colored red; the Φ_{chg} sub-site of the DRS is colored purple and the Φ_{hyd} sub-site is colored cyan. A bound ATP molecule is shown in stick representation.

Figure 2.

Partially assigned ^{15}N , ^1H TROSY spectrum of inactive full-length rat ERK2 at 800 MHz. The spectrum was acquired at 25° C, in a buffer containing 50 mM phosphate, 150 mM NaCl, 2 mM DTT, 500 μM EDTA at pH 6.8. The spectral parameters were: $\text{SW}_{1\text{H}}$ 15.0 ppm – 1024 complex points; $\text{SW}_{15\text{N}}$ 33.0 ppm – 128 complex points, recycling delay 1.5 s, 16 transients were used per t_1 point.

Figure 3.

Plots of the combined backbone chemical shift perturbations (calculated from amide ^{15}N , ^{13}C O and ^1H chemical shift changes in TROSY-based HNC0 experiments; see Table S1 footnote b) induced on inactive ERK2 by (A) a Ste-7 derived peptide, (B) an Elk-1 derived peptide, (C) *Ets* and (D) full-length PEA-15. Grey bars indicate resonances that disappear upon ligand binding. Also see Supplementary Table S1 for numerical values of the backbone chemical shift changes. Select helices and loops are shaded red and green respectively.

Figure 4.

Combined backbone chemical shift perturbations (^{15}N , ^1H and $^{13}\text{C}'$ from a TROSY-HNCO experiment) induced on ERK2 by a D-site peptide derived from (A) Ste-7 or (B) Elk-1 are plotted on a ribbon representation of inactive ERK2 (PDB ID: 2GPH) using a red-blue gradient. Important structural elements around the binding sites are labeled. Key residues including the conserved common docking D316 and D319 (from the Φ_{chg} sub-site) and H123 and Y126 (from the Φ_{hyd} sub-site) that form part of the D-recruitment site (DRS) are labeled. The gatekeeper residue (Q103) that is consistently perturbed is also labeled. Residues that disappear upon ligand binding are colored cyan. (C) The ribbon

representations for D-site peptides derived from the phosphatase HePTP (light green) bound to ERK2 (light green) as well from Ste-7 (dark green) bound to the yeast ortholog of ERK2, Fus3 (after superposition of Fus3 to ERK2) are shown. Key sidechains for the two ligands are also highlighted. The shading scheme for the ERK2 surface is the same as in (A) and (B). The chemical shift range has been scaled for coloring to ease visualization. Numerical values of the chemical shift changes can be found in Supplementary Table S1.

Figure 5.

Plots of absolute chemical shift changes for $^{13}\text{C}\alpha$ nuclei (obtained using TROSY-based HNCA experiments) induced on inactive ERK2 by (A) an Elk-1 derived peptide, (B) *Ets* and (C) PEA-15. Note that in (A) and (C), the shifts for H123 (3.4 ppm and 3.75 ppm, respectively) are larger than the ordinate axis window. Also see Supplementary Table S2 for numerical values of the $^{13}\text{C}\alpha$ chemical shift changes.

Figure 6. Combined backbone chemical shift perturbations (^{15}N , ^1H and $^{13}\text{C}'$ from a TROSY-HNCO experiment) induced by (A) *Ets* and (B) full-length PEA-15, are plotted on a ribbon representation of ERK2. Key residues are labeled as in Figure 4. Also labeled is the perturbed residue Y261 that has been suggested to form a part of the FRS from HXMS studies (21). The chemical shift range has been scaled for coloring to ease visualization. Actual shift changes can be found in Supplementary Table S1.